The connection between S1PR1 and STAT3 activation was fundamental in lymphoma, adenocarcinoma, melanoma, breast, and prostate cancers [78], and targeting S1PR1 to decrease expression of STAT3-regulated genes resulted in inhibition of tumor progression [79]. This evidence concerns the gene STAT3 and prostate cancer.